It is currently trading at $6.57 quite a bit below $7.42, the stock’s 50 day moving average and impressively lower than the 200 day moving average of $7.82. The 50 day moving average was down $-0.85 and the 200 day average went down by -16.04%. 94K shares changed hands in the last trading session. Overall, volume was down 4.18% under the stocks normal daily volume.
Investors are feeling more bullish on the company if you take note of the decrease in short interest. The stock experienced a fall in short interest from September 29, 2017 to October 13, 2017 of -0.23%. Short interest fell 4,428 over that timeframe. With short interest at 1,891,204 and short average daily volume at 113,390, the short-interest ratio is 17.0 and the percentage of shorted shares was 0.04% on October 13.
These firms have modified their investment in CCXI. As of the end of the quarter Cutler Group LP had bought 350 shares growing its position 426.8%. The value of the investment in (CCXI) went from $0 to $3,000 increasing inf% for the reporting period. Bank Of Montreal /can/ added to its investment by buying 1,069 shares an increase of 19.4% in the quarter. Bank Of Montreal /can/ now holds 6,566 shares valued at $49,000. The total value of its holdings decreased 3.9%.
Strs Ohio grew its stake by buying 10,500 shares an increase of 13.9%. Strs Ohio controls 86,000 shares with a value of $638,000. The value of the position overall is down by 9.6%. As of quarter end Simplex Trading, LLC had acquired a total of 312 shares growing its stake by 283.6%. The value of the total investment in ChemoCentryx, Inc. increased from $1,000 to $3,000 a change of $2,000 quarter to quarter.
As of the last earnings report the EPS was $-0.62 and is projected to be $-0.90 for the current year with 48,706,000 shares currently outstanding. Analysts expect next quarter’s EPS to be $-0.32 and the next full year EPS is anticipated to be $-1.36.
ChemoCentryx, Inc., launched on November 8, 1996, is a biopharmaceutical company. The Company is involved in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of the Business’s drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Business’s drug candidates are small molecules, which are orally administered. The Business’s late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS)..